Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyadic International, Inc. stock logo
DYAI
Dyadic International
$0.94
-5.6%
$1.19
$0.93
$2.67
$28.29M1.0168,641 shs53,526 shs
FibroGen, Inc. stock logo
FGEN
FibroGen
$0.32
-2.6%
$0.31
$0.18
$1.53
$32.49M0.862.05 million shs471,238 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.73
-5.9%
$0.92
$0.72
$2.60
$28.49M1.65160,693 shs412,611 shs
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
$0.33
-0.2%
$0.36
$0.29
$3.05
$7.69M1.29214,742 shs14,925 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyadic International, Inc. stock logo
DYAI
Dyadic International
0.00%-6.06%-15.61%-30.36%-48.93%
FibroGen, Inc. stock logo
FGEN
FibroGen
0.00%+5.23%+5.20%-33.47%-74.62%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00%-6.73%-23.92%-23.17%-66.98%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
0.00%-2.86%-4.89%-12.85%-87.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dyadic International, Inc. stock logo
DYAI
Dyadic International
2.554 of 5 stars
3.55.00.00.00.01.70.0
FibroGen, Inc. stock logo
FGEN
FibroGen
4.2054 of 5 stars
3.35.00.04.70.03.30.6
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
1.4301 of 5 stars
0.04.00.00.04.40.80.6
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
2.8305 of 5 stars
2.85.00.00.00.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dyadic International, Inc. stock logo
DYAI
Dyadic International
3.00
Buy$6.00538.30% Upside
FibroGen, Inc. stock logo
FGEN
FibroGen
2.50
Moderate Buy$10.003,010.42% Upside
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
1.50
Reduce$0.4535.50% Upside

Current Analyst Ratings Breakdown

Latest TSBX, FGEN, DYAI, and SCYX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
FibroGen, Inc. stock logo
FGEN
FibroGen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/1/2025
FibroGen, Inc. stock logo
FGEN
FibroGen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/18/2025
FibroGen, Inc. stock logo
FGEN
FibroGen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dyadic International, Inc. stock logo
DYAI
Dyadic International
$3.34M8.46N/AN/A$0.20 per share4.70
FibroGen, Inc. stock logo
FGEN
FibroGen
$7.00M4.64N/AN/A($1.87) per share-0.17
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$2.63M10.83$1.26 per share0.58$1.96 per share0.37
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
$19.31M0.40N/AN/A$4.27 per share0.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dyadic International, Inc. stock logo
DYAI
Dyadic International
-$6.80M-$0.20N/AN/AN/A-188.09%-149.16%-59.81%8/12/2025 (Estimated)
FibroGen, Inc. stock logo
FGEN
FibroGen
-$284.23M-$0.10N/AN/AN/A-67.66%N/A-36.17%8/5/2025 (Estimated)
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$67.04M-$0.56N/A14.60N/A-425.41%-66.21%-38.84%8/6/2025 (Estimated)
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$55.20M-$2.73N/AN/AN/AN/A-105.99%-87.27%8/13/2025 (Estimated)

Latest TSBX, FGEN, DYAI, and SCYX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
5/14/2025Q1 2025
Dyadic International, Inc. stock logo
DYAI
Dyadic International
N/A-$0.07N/A-$0.07N/A$0.39 million
5/12/2025Q1 2025
FibroGen, Inc. stock logo
FGEN
FibroGen
$0.03-$0.16-$0.19$0.05$2.00 million$2.70 million
5/8/2025Q1 2025
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$0.26-$0.51-$0.25-$0.51N/AN/A
3/28/2025Q4 2024
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
-$0.69-$0.56+$0.13-$0.56N/AN/A
3/26/2025Q4 2024
Dyadic International, Inc. stock logo
DYAI
Dyadic International
-$0.04-$0.05-$0.01-$0.05$1.60 million$0.82 million
3/17/2025Q4 2024
FibroGen, Inc. stock logo
FGEN
FibroGen
-$0.08-$0.08N/A$0.18$24.91 million$3.14 million
3/12/2025Q4 2024
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.22-$0.09+$0.13-$0.09N/A$0.98 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dyadic International, Inc. stock logo
DYAI
Dyadic International
N/AN/AN/AN/AN/A
FibroGen, Inc. stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dyadic International, Inc. stock logo
DYAI
Dyadic International
1.54
5.15
5.15
FibroGen, Inc. stock logo
FGEN
FibroGen
N/A
1.28
1.16
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
3.13
3.13
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
N/A
3.75
3.75

Institutional Ownership

CompanyInstitutional Ownership
Dyadic International, Inc. stock logo
DYAI
Dyadic International
27.95%
FibroGen, Inc. stock logo
FGEN
FibroGen
72.71%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
52.51%

Insider Ownership

CompanyInsider Ownership
Dyadic International, Inc. stock logo
DYAI
Dyadic International
29.50%
FibroGen, Inc. stock logo
FGEN
FibroGen
3.07%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
32.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dyadic International, Inc. stock logo
DYAI
Dyadic International
730.09 million21.07 millionOptionable
FibroGen, Inc. stock logo
FGEN
FibroGen
570101.04 million98.78 millionOptionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million36.87 millionOptionable
Turnstone Biologics Corp. stock logo
TSBX
Turnstone Biologics
8223.14 million15.70 millionNot Optionable

Recent News About These Companies

Turnstone Biologics reports Q4 EPS (56c) vs (73c) last year
Turnstone Biologics to explore strategic alternatives
BofA downgrades Turnstone to Underperform on unfavorable market
Turnstone Biologics downgraded to Underperform from Neutral at BofA
Turnstone Biologics Faces Financial and Operational Challenges

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dyadic International stock logo

Dyadic International NASDAQ:DYAI

$0.94 -0.06 (-5.60%)
Closing price 04:00 PM Eastern
Extended Trading
$0.96 +0.02 (+1.70%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

FibroGen stock logo

FibroGen NASDAQ:FGEN

$0.32 -0.01 (-2.58%)
Closing price 04:00 PM Eastern
Extended Trading
$0.32 +0.00 (+0.47%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.73 -0.05 (-5.93%)
Closing price 04:00 PM Eastern
Extended Trading
$0.74 +0.01 (+1.78%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Turnstone Biologics stock logo

Turnstone Biologics NASDAQ:TSBX

$0.33 0.00 (-0.24%)
Closing price 03:52 PM Eastern
Extended Trading
$0.34 +0.01 (+1.78%)
As of 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.